Role of biomarkers in the clinical management of glioblastomas: what are the barriers and how can we overcome them?

被引：14

作者：

McDonald, Kerrie L. ^{[1
]}

Aw, Grace ^{[1
]}

Kleihues, Paul ^{[1
]}

机构：

[1] Univ New S Wales, Prince Wales Clin Sch, Lowy Canc Res Ctr, POB 1, Kensington, NSW 2033, Australia

来源：

FRONTIERS IN NEUROLOGY | 2013年 / 3卷

关键词：

biomarkers; treatment response; glioblastoma; MGMT; tumor heterogeneity; NEWLY-DIAGNOSED GLIOBLASTOMA; GROWTH-FACTOR RECEPTOR; DNA-REPAIR GENE; PHASE-II TRIAL; INTEGRATED GENOMIC ANALYSIS; PROMOTER HYPERMETHYLATION; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ADJUVANT TEMOZOLOMIDE; TUMOR-SUPPRESSOR; MALIGNANT GLIOMA;

D O I：

10.3389/fneur.2012.00188

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Thousands of articles describing biomarkers predictive of treatment and prognostic of survival in cancer have been published, yet only a handful of biomarkers are currently used routinely in the clinic. Biomarkers need to be analytically standardized, validated, and clinically useful. This review will address the challenges and ways in which we can improve our discovery and translation of prospective biomarkers from the lab into validated diagnostic tests with a specific focus on patients diagnosed with glioblastoma and MGMT promoter methylation status. There has been long-held enthusiasm to use MGMT promoter methylation as a predictive biomarker for patients treated with the alkylating agent, temozolomide; however in the majority of centers around the world, this has not yet transpired.

引用

页数：8

共 50 条

[1] Viewpoint Barriers to low-carbon design: what are they and how can we overcome them?
Thomas, Claire
[J]. Structural Engineer, 2022, 100 (09): : 30 - 31
[2] What are the economic barriers of antibiotic R&D and how can we overcome them?
Renwick, Mathew
Mossialos, Elias
[J]. EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (10) : 889 - 892
[3] Negotiation and Career Advancement: How Can We Continue to Advance Women in Academic Surgery, What Are the Barriers They Are Facing, and What Can We Do to Overcome Them?
Turfah, Mary
Kwakye, Gifty
[J]. CLINICS IN COLON AND RECTAL SURGERY, 2023, 36 (05) : 321 - 326
[4] Less is difficult Barriers in the Implementation of sufficient Lifestyles - and how we can overcome them
Stengel, Oliver
[J]. GAIA-ECOLOGICAL PERSPECTIVES FOR SCIENCE AND SOCIETY, 2011, 20 (01): : 26 - 30
[5] What are the barriers to our profession, and how can we remove them?
Pownall, Madeleine
Brookman-Byrne, Annie
[J]. PSYCHOLOGIST, 2021, 34 : 30 - 38
[6] What are the current limitations for HSC transduction? How can we overcome them? Discussion
Nienhuis, A
Moore, MAS
Dick, JE
Stamatoyannopoulos, G
Lemischka, IR
TorokStorb, B
Spangrude, GJ
Papayannopoulou, T
Flugel, RM
Orlic, D
Broxmeyer, HE
Quesenberry, PJ
Sharkis, SJ
Lansdorp, PM
[J]. STEM CELLS, 1997, 15 : 255 - 263
[7] Clinical research with adolescents: barriers and how to overcome them
Sokkary, Nancy
Yoost, Jennie
[J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2018, 30 (05) : 300 - 304
[8] Skin Barriers in Dermal Drug Delivery: Which Barriers Have to Be Overcome and How Can We Measure Them?
Gorzelanny, Christian
Mess, Christian
Schneider, Stefan W.
Huck, Volker
Brandner, Johanna M.
[J]. PHARMACEUTICS, 2020, 12 (07) : 1 - 31
[9] What Are the Main Roadblocks to Transnational Biobank Collaboration, and How Can We Overcome Them?
Watson, Peter H.
Ravid, Rivka
Eng, Chon Boon
Litton, Jan-Eric
Vaught, Jim
Matusan, Anita
[J]. BIOPRESERVATION AND BIOBANKING, 2011, 9 (03) : 213 - 216
[10] Barriers to Social Media and How SMEs Can Overcome Them
Roy, Andree
Dionne, Claude
Maxwell, Lauren
Carson, Marsha
Sosa, Otoniel
[J]. PROCEEDINGS OF THE 5TH EUROPEAN CONFERENCE ON SOCIAL MEDIA (ECSM 2018), 2018, : 255 - 263

← 1 2 3 4 5 →